WB, IP
H M R Mk
Endogenous
16
Rabbit IgG
#Q9Y244
51371
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:200 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Species predicted to react based on 100% sequence homology
The antigen sequence used to produce this antibody shares
100% sequence homology with the species listed here, but
reactivity has not been tested or confirmed to work by CST.
Use of this product with these species is not covered under
our
Product Performance Guarantee.
Bovine
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human POMP protein.
Background
The 26S proteasome is a highly abundant proteolytic complex involved in the degradation of ubiquitinated substrate proteins. It consists largely of the 20S catalytic core particle (CP) and the 19S/PA700 regulatory particle (RP) that caps either end of the CP. The CP consists of two stacked heteroheptameric β-rings (β1-7) that contain three catalytic β-subunits flanked on either side by two heteroheptameric α-rings (α1-7). The RP includes multimeric base and lid complexes. The RP base includes a heterohexameric ring of ATPase subunits that unfold the substrate and open the α-subunit gate to expose the substrate to the catalytic β-subunits. The lid consists of ubiquitin receptors and DUBs that recruit ubiquitinated substrates and modify ubiquitin chain topology (1,2). Proteasome activity modulators, such as PA28/11S REG, bind the 20S CP cylinder end and open the CP channel (1,2).
Proteasome maturation protein (POMP, proteassemblin, hUMP1) is an integral factor essential for assembly of the 20S catalytic core particle during mammalian proteasome biogenesis. POMP promotes heteroheptameric β-ring formation and dimerization of half-proteasomes during core particle assembly. The POMP protein undergoes proteasomal degradation following 20S CP complex assembly and activation (3-6). Research studies suggest that POMP is required for CP assembly for both constitutive proteasomes and immunoproteasomes, and that the assembly focal point resides at the endoplasmic reticulum (6-8). A single nucleotide deletion in the 5' UTR of POMP results in altered epidermal POMP distribution and the autosomal recessive skin disorder known as KLICK syndrome (9).
- Finley, D. (2009) Annu Rev Biochem 78, 477-513.
- Lee, M.J. et al. (2011) Mol Cell Proteomics 10, R110.003871.
- Griffin, T.A. et al. (2000) Mol Cell Biol Res Commun 3, 212-7.
- Witt, E. et al. (2000) J Mol Biol 301, 1-9.
- Ramos, P.C. et al. (1998) Cell 92, 489-99.
- Fricke, B. et al. (2007) EMBO Rep 8, 1170-5.
- Heink, S. et al. (2005) Proc Natl Acad Sci U S A 102, 9241-6.
- Heink, S. et al. (2006) Cancer Res 66, 649-52.
- Dahlqvist, J. et al. (2010) Am J Hum Genet 86, 596-603.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
